Stock Market Reviews

CMPX (Compass Therapeutics, Inc.) News

Get the latest news, insights, and market updates on CMPX (Compass Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement
  With strong three-month performance and significant upside potential, Compass Therapeutics, Inc. (NASDAQ:CMPX) secures a spot on our list of the 12 hot penny stocks to invest in right now. On November 10, 2025, H.C. Wainwright’s Joseph Pantginis reiterated a “Buy” rating on Compass Therapeutics, Inc. (NASDAQ:CMPX) with a $24 price target. The company’s advancing pipeline, […]
  Dec 1, 2025 - $CMPX
• Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade
  The mean of analysts' price targets for Compass Therapeutics, Inc. (CMPX) points to a 154.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Nov 26, 2025 - $CMPX
• Compass Therapeutics to Participate in Upcoming December Investor Events
  BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of December. Details are as follows: Piper Sandler 37th Annual Healthcare Conference Location: New York, NYDate: Tuesday, December 2, 2025 Time: 8:00 AM ET Webcast Link: https://event.webcasts.com/start
  Nov 25, 2025 - $CMPX
• Zacks.com featured highlights include Orla Mining, FIGS and Compass Therapeutics
  Orla Mining, FIGS and Compass Therapeutics have been highlighted in this Screen of The Week article.
  Nov 24, 2025 - $CMPX
• 2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
  ORLA, FIGS and CMPX emerge as breakout candidates as traders scan for stocks nearing or clearing key resistance levels.
  Nov 20, 2025 - $CMPX
• Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development
  Compass Therapeutics Inc. (NASDAQ:CMPX) is a must-buy penny stock to buy now. On November 10, Pipe Sandler analyst Biren Amin reiterated that Compass Therapeutics Inc. (NASDAQ:CMPX) is a Buy and set a $12 price target. The positive stance stems from the company’s announcement that it has made significant progress in developing its clinical pipeline. HC […]
  Nov 18, 2025 - $CMPX
• High Growth Tech Stocks In The US Market November 2025
  In the midst of a volatile U.S. market, where concerns about AI valuations have led to fluctuations in major indices like the Dow Jones and Nasdaq, investors are closely watching earnings reports and economic indicators amid a historic government shutdown. As tech stocks face renewed scrutiny, identifying high-growth opportunities requires careful consideration of companies' adaptability to current trends and their potential for innovation in an uncertain economic landscape.
  Nov 6, 2025 - $CMPX
• Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026.A new response in a third indication has been observed in the fifth and final dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); no dose-limiting toxi
  Nov 5, 2025 - $CMPX
• Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
  CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed select competitive antibodies in the class, including ivonescimab, in controlling tumor growth across multiple xenograft and syngeneic models.IND submission is on track for Q4 2025. BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focus
  Nov 4, 2025 - $CMPX
• Institutional investors in Compass Therapeutics, Inc. (NASDAQ:CMPX) lost 9.0% last week but have reaped the benefits of longer-term growth
  Key Insights Significantly high institutional ownership implies Compass Therapeutics' stock price is sensitive to their...
  Nov 3, 2025 - $CMPX